查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576740

额颞叶疾病治疗市场：按治疗类型、治疗阶段、给药方法、最终用户分类 - 全球预测 2025-2030

Frontotemporal Disorders Treatment Market by Therapy Type (Medication, Occupational Therapy, Physical Therapy), Treatment Stage (Early Stage, Late Stage, Mid Stage), Mode Of Administration, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年额颞叶疾病治疗市场价值为3.5467亿美元，预计到2024年将达到3.6928亿美元，复合年增长率为4.02%，到2030年将达到4.6763亿美元。

额颞叶疾病 (FTD) 包括一组影响额颞叶的脑部疾病，导致行为、性格、语言和运动技能进行性恶化。这些疾病的盛行率不断上升，因此需要治疗市场，这凸显了对改善诊断技术、标靶治疗和支持性治疗以提高患者生活品质的需求。主要应用包括诊断辅助、药物介入以及新兴基因和细胞疗法。最终用途范围包括专注于治疗神经退化性疾病的医院、专科诊所、研究机构和製药公司。市场成长受到神经影像技术进步、对 FTD病理学的更好理解以及未满足的医疗需求激增等因素的影响。创新药物开发存在机会，特别是在 FTD 特异性生技药品和精准医学领域。扩大临床试验并促进生物技术公司和学术研究机构之间的合作可以进一步增加市场潜力。然而，FDA核准的治疗方法数量有限、研发成本高昂以及早期诊断方面的挑战等挑战持续阻碍市场加速。北美和欧洲等人口老化地区是特别紧迫的市场，这些地区的医疗基础设施支持先进的研究和治疗。对市场相关人员的建议包括投资人工智慧驱动的诊断工具，并探索个人化医疗方法来解决 FTD 的遗传变异问题。由于目前的治疗选择有限且监管途径详细，早期检测方法和支持性护理技术的创新将使市场参与企业脱颖而出。我们对跨领域研究的持续关注可以带来显着改变缓解疾病治疗所需的突破。该市场的性质受到严格监管，重点关注临床疗效、安全性和全面的患者照护管理，推动融合神经病学和生物技术的多学科方法。

主要市场统计
基准年[2023] 3.5467亿美元
预测年份 [2024] 36928万美元
预测年份 [2030] 46763万美元
复合年增长率（%） 4.02%

市场动态：揭示快速发展的额颞叶疾病治疗市场的关键市场洞察

供需的动态交互作用正在改变额颞叶疾病治疗市场。了解这些不断变化的市场动态可以帮助企业做出明智的投资决策、策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 增加医疗支出和政府支持神经系统疾病治疗的努力
    • 扩大医疗基础设施以改善额颞叶疾病的诊断和治疗
    • 製药公司之间的合作研究和联盟，以促进额颞叶疾病治疗方法的研究和开发
  • 市场限制因素
    • 开发额颞叶疾病治疗方法的高成本会影响患者的经济负担
    • 医疗专业人员对额颞叶疾病早期诊断与治疗的认知较低
  • 市场机会
    • 增加政府对额颞叶疾病治疗研究的资助和倡议
    • 更多采用个人化医疗和标靶治疗（额颞叶疾病治疗）
    • 早期发现额颞叶疾病的诊断工具和技术的进展
  • 市场问题
    • 来自学名药和新兴生物技术的竞争加剧
    • 疾病机制的复杂性影响通用治疗方法的发展

波特五力：驾驭额颞叶疾病治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点，避免潜在的挑战，确保更强大的市场地位。

PESTLE分析：了解额颞叶疾病治疗市场的外在影响

外部宏观环境因素在塑造额颞叶失调治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解额颞叶疾病治疗市场的竞争状况

额颞叶疾病治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵额颞叶疾病治疗市场供应商的绩效评估

FPNV 定位矩阵是评估额颞叶疾病治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划额颞叶疾病治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，额颞叶疾病治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 医疗费用上涨和政府支持神经系统疾病治疗的努力
      • 扩大医疗基础设施，以更好地诊断和治疗额颞叶疾病
      • 製药公司之间的合作与伙伴关係，促进额颞叶疾病治疗的研发
    • 抑制因素
      • 开发额颞叶疾病治疗方法的高昂费用影响患者的支付能力
      • 医疗保健专业人员对额颞叶疾病早期诊断和治疗的认识较低
    • 机会
      • 增加政府对额颞叶疾病治疗研究的资助和承诺
      • 扩大采用个人化医疗和标靶治疗治疗额颞叶疾病
      • 早期识别额颞叶疾病的诊断工具和技术的进展
    • 任务
      • 来自学名药和新兴生物技术的竞争加剧
      • 疾病机制的复杂性影响通用治疗方法的发展
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章额颞叶疾病治疗市场：依治疗类型

  • 介绍
  • 药物治疗
    • 抗忧郁症
    • 抗精神病药
    • 情绪稳定剂
  • 职能治疗
    • 辅助器具培训
    • 日常生活技能
  • 物理治疗
    • 弹性练习
    • 肌力训练
  • 语言治疗
    • 非语言技巧
    • 语言技巧

第七章额颞叶疾病治疗市场：依治疗阶段

  • 介绍
  • 早期的
    • 预防措施
  • 后期
    • 安宁疗护
  • 中场
    • 症状管理

第八章额颞叶疾病治疗市场：依管理法

  • 介绍
  • 注射
    • 肌肉注射
    • 静脉
  • 鼻内
    • 喷
  • 口服
    • 胶囊
    • 锭剂
  • 经皮的
    • 凝胶
    • 修补

第九章额颞叶疾病治疗市场：依最终用户

  • 介绍
  • 居家医疗
  • 医院
    • 综合医院
    • 专科医院
  • 长期照护中心
  • 研究所
  • 专科诊所

第10章北美和南美的额颞叶疾病治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区额颞叶疾病治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的额颞叶疾病治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-535C62918B38

The Frontotemporal Disorders Treatment Market was valued at USD 354.67 million in 2023, expected to reach USD 369.28 million in 2024, and is projected to grow at a CAGR of 4.02%, to USD 467.63 million by 2030.

Frontotemporal disorders (FTD) encompass a group of brain disorders affecting the fronto-temporal lobes, leading to progressive deterioration in behavior, personality, language, and motor skills. The treatment market is necessitated by the growing prevalence of these disorders, emphasizing the need for improved diagnostic techniques, targeted therapies, and supportive treatments that can enhance patient quality of life. Applications predominantly include diagnostic aids, pharmaceutical interventions, and emerging gene and cell therapies. The end-use scope covers hospitals, specialty clinics, research institutions, and pharmaceutical companies focusing on neurodegenerative disease treatment. Market growth is influenced by factors such as advancements in neuroimaging technologies, increased understanding of FTD pathophysiology, and a surge in unmet medical needs. Opportunities exist in innovative drug development, particularly in biologics and precision medicine tailored specifically for FTD. Expanding clinical trials and fostering collaborations between biotechnology firms and academic research institutions could further propel market potential. However, challenges prevail in the form of limited FDA-approved treatments, high costs associated with R&D, and challenges in early-stage diagnosis, which continue to impede market acceleration. Regions with aging populations are particularly pressing markets, such as North America and Europe, where healthcare infrastructure supports advanced research and treatment accessibility. Recommendations for market players include investing in AI-driven diagnostic tools and exploring personalized medicine approaches to address genetic variances in FTD. Due to limited current therapeutic options and detailed regulatory pathways, innovation in early detection methodologies and supportive care technologies can differentiate market participants. Continued focus on cross-disciplinary research can yield breakthroughs necessary for dramatic shifts in disease-modifying treatments. The nature of the market is tightly regulated with a focus on clinical efficacy, safety, and comprehensive patient care management, pushing an interdisciplinary approach blending neurology and biotechnology.

KEY MARKET STATISTICS
Base Year [2023] USD 354.67 million
Estimated Year [2024] USD 369.28 million
Forecast Year [2030] USD 467.63 million
CAGR (%) 4.02%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Frontotemporal Disorders Treatment Market

The Frontotemporal Disorders Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising healthcare expenditure and government initiatives to support neurological disorder treatments
    • Expansion of healthcare infrastructure enabling better diagnosis and treatment of frontotemporal disorders
    • Collaborations and partnerships between pharmaceutical companies driving research and development in frontotemporal disorder therapies
  • Market Restraints
    • High cost associated with the development of frontotemporal disorder treatments impacting patient affordability
    • Low awareness among medical professionals about early diagnosis and treatment for frontotemporal disorders
  • Market Opportunities
    • Increased government funding and initiatives for research in frontotemporal disorders treatments
    • Growing adoption of personalized medicine and targeted therapies for frontotemporal disorders treatment
    • Advancements in diagnostic tools and techniques to identify frontotemporal disorders at early stages
  • Market Challenges
    • Increasing competition from generic drugs and emerging biotechnologies
    • Complexity of disease mechanisms affects the development of a one-size-fits-all treatment

Porter's Five Forces: A Strategic Tool for Navigating the Frontotemporal Disorders Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Frontotemporal Disorders Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Frontotemporal Disorders Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Frontotemporal Disorders Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Frontotemporal Disorders Treatment Market

A detailed market share analysis in the Frontotemporal Disorders Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Frontotemporal Disorders Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Frontotemporal Disorders Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Frontotemporal Disorders Treatment Market

A strategic analysis of the Frontotemporal Disorders Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Frontotemporal Disorders Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alector, Inc., Amgen Inc., AstraZeneca plc, Biogen Inc., Denali Therapeutics Inc., Eli Lilly and Company, Genentech, Inc., GlaxoSmithKline plc, Ionis Pharmaceuticals, Inc., Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., Prothena Corporation plc, Roche Holding AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, TauRx Pharmaceuticals Ltd., and Wave Life Sciences Ltd..

Market Segmentation & Coverage

This research report categorizes the Frontotemporal Disorders Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Medication, Occupational Therapy, Physical Therapy, and Speech Therapy. The Medication is further studied across Antidepressants, Antipsychotics, and Mood Stabilizers. The Occupational Therapy is further studied across Assistive Devices Training and Daily Living Skills. The Physical Therapy is further studied across Mobility Exercises and Strength Training. The Speech Therapy is further studied across Nonverbal Techniques and Verbal Techniques.
  • Based on Treatment Stage, market is studied across Early Stage, Late Stage, and Mid Stage. The Early Stage is further studied across Preventive Measures. The Late Stage is further studied across Palliative Care. The Mid Stage is further studied across Symptom Management.
  • Based on Mode Of Administration, market is studied across Injectable, Intranasal, Oral, and Transdermal. The Injectable is further studied across Intramuscular and Intravenous. The Intranasal is further studied across Sprays. The Oral is further studied across Capsules and Tablets. The Transdermal is further studied across Gels and Patches.
  • Based on End User, market is studied across Homecare Settings, Hospitals, Long-Term Care Centers, Research Institutes, and Specialty Clinics. The Hospitals is further studied across General Hospitals and Specialized Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising healthcare expenditure and government initiatives to support neurological disorder treatments
      • 5.1.1.2. Expansion of healthcare infrastructure enabling better diagnosis and treatment of frontotemporal disorders
      • 5.1.1.3. Collaborations and partnerships between pharmaceutical companies driving research and development in frontotemporal disorder therapies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the development of frontotemporal disorder treatments impacting patient affordability
      • 5.1.2.2. Low awareness among medical professionals about early diagnosis and treatment for frontotemporal disorders
    • 5.1.3. Opportunities
      • 5.1.3.1. Increased government funding and initiatives for research in frontotemporal disorders treatments
      • 5.1.3.2. Growing adoption of personalized medicine and targeted therapies for frontotemporal disorders treatment
      • 5.1.3.3. Advancements in diagnostic tools and techniques to identify frontotemporal disorders at early stages
    • 5.1.4. Challenges
      • 5.1.4.1. Increasing competition from generic drugs and emerging biotechnologies
      • 5.1.4.2. Complexity of disease mechanisms affects the development of a one-size-fits-all treatment
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Frontotemporal Disorders Treatment Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Medication
    • 6.2.1. Antidepressants
    • 6.2.2. Antipsychotics
    • 6.2.3. Mood Stabilizers
  • 6.3. Occupational Therapy
    • 6.3.1. Assistive Devices Training
    • 6.3.2. Daily Living Skills
  • 6.4. Physical Therapy
    • 6.4.1. Mobility Exercises
    • 6.4.2. Strength Training
  • 6.5. Speech Therapy
    • 6.5.1. Nonverbal Techniques
    • 6.5.2. Verbal Techniques

7. Frontotemporal Disorders Treatment Market, by Treatment Stage

  • 7.1. Introduction
  • 7.2. Early Stage
    • 7.2.1. Preventive Measures
  • 7.3. Late Stage
    • 7.3.1. Palliative Care
  • 7.4. Mid Stage
    • 7.4.1. Symptom Management

8. Frontotemporal Disorders Treatment Market, by Mode Of Administration

  • 8.1. Introduction
  • 8.2. Injectable
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
  • 8.3. Intranasal
    • 8.3.1. Sprays
  • 8.4. Oral
    • 8.4.1. Capsules
    • 8.4.2. Tablets
  • 8.5. Transdermal
    • 8.5.1. Gels
    • 8.5.2. Patches

9. Frontotemporal Disorders Treatment Market, by End User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals
    • 9.3.1. General Hospitals
    • 9.3.2. Specialized Hospitals
  • 9.4. Long-Term Care Centers
  • 9.5. Research Institutes
  • 9.6. Specialty Clinics

10. Americas Frontotemporal Disorders Treatment Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Frontotemporal Disorders Treatment Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Frontotemporal Disorders Treatment Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alector, Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca plc
  • 5. Biogen Inc.
  • 6. Denali Therapeutics Inc.
  • 7. Eli Lilly and Company
  • 8. Genentech, Inc.
  • 9. GlaxoSmithKline plc
  • 10. Ionis Pharmaceuticals, Inc.
  • 11. Johnson & Johnson
  • 12. Merck & Co., Inc.
  • 13. Novartis AG
  • 14. Pfizer Inc.
  • 15. Prothena Corporation plc
  • 16. Roche Holding AG
  • 17. Sanofi S.A.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. TauRx Pharmaceuticals Ltd.
  • 20. Wave Life Sciences Ltd.

LIST OF FIGURES

  • FIGURE 1. FRONTOTEMPORAL DISORDERS TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. FRONTOTEMPORAL DISORDERS TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. FRONTOTEMPORAL DISORDERS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. FRONTOTEMPORAL DISORDERS TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. FRONTOTEMPORAL DISORDERS TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ANTIPSYCHOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MOOD STABILIZERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ASSISTIVE DEVICES TRAINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY DAILY LIVING SKILLS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MOBILITY EXERCISES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY STRENGTH TRAINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY NONVERBAL TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY VERBAL TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PREVENTIVE MEASURES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PALLIATIVE CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SYMPTOM MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPECIALIZED HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LONG-TERM CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. GLOBAL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 71. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 72. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 73. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 74. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 76. AMERICAS FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 83. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 84. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 85. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 86. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 88. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 89. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 90. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 91. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. ARGENTINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 99. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 100. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 101. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 102. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 104. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 105. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 106. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 107. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. BRAZIL FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 109. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 113. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 115. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 116. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 117. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 118. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 120. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 121. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 122. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 123. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. CANADA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 125. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 129. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 130. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 131. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 132. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 133. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 134. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 136. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 137. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 138. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 139. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. MEXICO FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 154. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 155. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 157. UNITED STATES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 175. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 181. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 182. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 183. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 184. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 186. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 187. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 188. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 189. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. AUSTRALIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 191. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 194. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 197. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 198. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 199. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 200. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 202. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 203. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 204. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 205. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. CHINA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 207. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 210. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 211. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 212. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 213. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 214. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 215. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 216. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 217. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 218. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 219. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 220. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 221. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. INDIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 223. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 225. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 229. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 230. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 231. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 232. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 234. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 235. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 236. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 237. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. INDONESIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 239. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 241. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 242. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 243. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 244. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 245. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 246. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 247. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 248. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 250. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 251. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 252. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 253. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 254. JAPAN FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 255. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 257. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 258. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 259. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 260. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 261. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 262. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 263. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 264. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 265. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 266. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 267. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 268. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 269. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. MALAYSIA FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 271. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 273. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 274. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 275. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 276. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 277. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 278. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 279. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 280. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 282. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 283. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 284. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
  • TABLE 285. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. PHILIPPINES FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 287. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 289. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY OCCUPATIONAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 290. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY SPEECH THERAPY, 2018-2030 (USD MILLION)
  • TABLE 292. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TREATMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 293. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY EARLY STAGE, 2018-2030 (USD MILLION)
  • TABLE 294. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY LATE STAGE, 2018-2030 (USD MILLION)
  • TABLE 295. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MID STAGE, 2018-2030 (USD MILLION)
  • TABLE 296. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 297. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 298. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY INTRANASAL, 2018-2030 (USD MILLION)
  • TABLE 299. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
  • TABLE 300. SINGAPORE FRONTOTEMPORAL DISORDERS TREATMENT MARKET SIZE, BY TRAN